Abstract 357P
Background
Advanced Head and neck cancer despite multimodal treatment is associated with disfigurement, extreme pain, and psychological distress. To study the effects of a multimodal palliative approach involving psychological counselling, psychometric dug therapy and pain-relieving blocks to ameliorate the total pain state of such patient during end of life care.
Methods
This is a prospective, single-arm observational study conducted on 20 head and neck cancer patients, from January 2015 to December 2018. Patients who were on palliative treatment were processed for self-report of severe psychological distress and intractable pain by means of innovative distress score and quality of life index and the numeric pain rating scale and given combination therapy with antidepressants, antipsychotics, pain killers and neurolytic blocks along with repeated counselling sessions.
Results
20 patients were included in this study, of which 66.6 % were males and 33.3% were female. Age range was 44-79 years and they had mean pain scores of 7.61 (SD 1.577) before the intervention and mean distress scores of 8.33 (SD 1.237) suffering for a duration of 72.5 days (SD 24.81). A significant reduction in pain was noted by a decrease in mean Numeric rating scale to 2.83 (SD 0.618) and extension of the mean duration of analgesia to 24.33 days (SD 6.84) and reduction in distress score to 3.78 (SD 0.732). Pre- and post-procedure mean morphine requirement was also significantly reduced, at the end of 2 weeks. Significant easing of distress and improvement in performance was observed in all patients.
Conclusions
The application of a multimodal palliative approach to progressive head and neck cancer patients is an easy, safe, and cost-effective method to improve quality of life. Medical oncologists must be sensitized to elicit and measure the distress in such patients. Counseling sessions and pharmacotherapy, if indicated, are very effective in the care of such patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract